You evaluate pipelines, IP, and market risk across many companies from the outside. ClinicaLister turns days of manual diligence into a sourced company dossier your AI assistant assembles in minutes — with patent-cliff and market-size analysis no single public database gives you.
The highest-leverage things ClinicaLister does for a investor / bd analyst.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| Deal sourcing / screening a therapeutic area | See which indications are crowded and which are white space, ranked by how many sponsors and trials compete in each. | Both | days of cross-ref → a density map in one pass | High |
| Pipeline due diligence on a target | Reconstruct a sponsor's entire pipeline — maturity, diversification, and termination or approval status — in a single rollup. | Both | whole pipeline in minutes vs a multi-day desk exercise | High |
| Competitive landscape for one asset | Map every competing molecule, trial, sponsor, and site around one asset without hopping between portals. | Both | full asset landscape without portal-hopping | High |
| Patent-cliff / LoE + revenue-at-risk | A colour-coded cliff timeline pairs patent and loss-of-exclusivity dates with a Medicare revenue proxy to rank which assets have the most revenue at risk. | Both | acquisition-target / short-thesis finder | High |
| Market sizing / TAM proxy | Your AI assistant builds a per-drug Medicare revenue proxy as a first-cut read on market size. | MCP | Medicare revenue proxy per drug — not charted in the app | Medium |
| Comparable / benchmark analysis | Rank peers on approval speed and IP strength to build comparables without hand-assembling comps. | MCP | peer benchmarking without hand-built comps | High |
| Investment-thesis build | A sourced company brief pulls catalysts, IP, and competitive density into a bull/bear scaffold to build a thesis on. | MCP | bull/bear scaffold from sourced data | Medium |
| Catalyst / readout / approval tracking | Newly posted trials, sponsor activity, and severity-ranked alerts surface catalysts in hours, plotted on an approval timeline. | Both | catalysts in hours, not after the print | High |
| Biosimilar / generic threat assessment | Track approved biosimilars and generics against each reference drug, with loss-of-exclusivity urgency to time the erosion. | Both | quantifies erosion timing per incumbent | High |
| White-space identification | Surface under-competed indications to aim a new-company or in-licensing thesis at open fields. | Both | points a new-co / in-licensing thesis at open fields | High |
| Portfolio-holdings monitoring | One saved auto-following query watches a whole list of sponsors at once and alerts you to field-level changes — no re-running searches. | App | live watch on a watchlist, no re-runs | High |
| Red-team / risk assessment | Supply-chain shortage signals, safety flags, and protocol-change churn combine into a structured downside register. | Both | a structured downside register | Medium |
| One-shot company brief | Point your AI assistant at a public sponsor and get pipeline, competition, safety, regulatory, geography, and recent changes in one deliverable. | MCP | IC-ready dossier from a single ask | High |
Straight answers on where ClinicaLister stops today — so there are no surprises.
US payer proxy, not global TAM. Market sizing draws on US Medicare pricing and spend only — no commercial-payer, ex-US, or epidemiology-based market size, and it's a report your AI assistant builds, not a chart in the app.
No valuation or deal data. There are no cap tables, burn, revenue, deal terms, or multiples, and no private-company or pre-clinical financials — ClinicaLister surfaces the sourced evidence, but the model is yours.
A public-registry ceiling. Undisclosed deals, stealth-mode assets, and pre-registration programs are invisible — absence of data is not absence of activity.
AI links are scored suggestions, not facts. Every trial-to-drug-to-patent link carries a confidence tier and its provenance; safety and shortage signals are candidates for your review.
Not a data terminal or API. There's no live feed or bulk export — output is synthesized reports refreshed through the day, with no earnings calendar or price and volume signals.
Point your AI assistant at any public sponsor and get a sourced pipeline, competition, IP, and market-risk brief in minutes — with patent-cliff-against-revenue analysis to rank which assets are most exposed.